Omada Health, INC 8-K filings

Omada Health announced robust Q2 2026 financial results, including 43% year-over-year revenue growth and a shift to net income, alongside a planned CEO transition.

Omada Health, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected directors Sean Duffy and Trevor Fetter and ratified the appointment of Deloitte & Touche LLP as its independent auditor.

Omada Health announced robust fourth-quarter and full-year 2025 results, featuring significant revenue and member growth, alongside achieving positive net income in Q4 and positive Adjusted EBITDA for the full year.

Omada Health announced preliminary, unaudited revenue for Q4 and full year 2025, showing significant growth and increased member count, ahead of its J.P. Morgan Healthcare Conference presentation.

Omada Health reports strong third-quarter 2025 results with significant revenue growth, reduced net loss, positive Adjusted EBITDA, and a new GLP-1 offering.

Omada Health reported strong second quarter 2025 financial results, with revenue increasing 49% year-over-year and significant progress towards profitability.

Omada Health, Inc. successfully completed its initial public offering, raising $172.6 million in gross proceeds and simultaneously enacting a comprehensive set of restated corporate governance documents.